{"id":"NCT00875394","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)","officialTitle":"A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02-01","primaryCompletion":"2008-06-27","completion":"2008-06-27","firstPosted":"2009-04-03","resultsPosted":"2011-04-20","lastUpdate":"2017-05-30"},"enrollment":68,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"],"interventions":[{"type":"DRUG","name":"sitagliptin phosphate","otherNames":["sitagliptin"]},{"type":"DRUG","name":"Comparator: metformin","otherNames":["metformin"]},{"type":"DRUG","name":"Comparator: metformin","otherNames":["metformin"]},{"type":"DRUG","name":"Comparator: Antidiabetic Standard of Care","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"3","type":"ACTIVE_COMPARATOR"}],"summary":"After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24","timeFrame":"Baseline and 24 weeks","effectByArm":[],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":["Nausea","Cough"]}}